Claims

5

10

15

20

25

1. A compound represented by the following formula, a salt thereof or a hydrate of the foregoing:

$$R^{4}$$
 R^{5}
 R^{8}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{9}
 R^{1}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{9}
 R^{1}
 R^{2}
 R^{1}
 R^{2}

wherein R¹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, C₁₋₆ alkoxy, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group or a group represented by the formula -NR^{11a}R^{11b}, and R¹ may be substituted with a substituent selected from Substituent Group A or Substituent Group B, wherein R^{11a} and R^{11b} may be the same or different and each represents hydrogen, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, C₁₋₆ alkoxy, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R^{11a} and R^{11b} may be substituted with a substituent selected from Substituent Group A or Substituent Group B;

R² and R³ represent hydrogen;

 R^4 , R^5 , R^6 and R^7 may be the same or different and each represents hydrogen, halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino, di- C_{1-6} alkylamino or a group represented by the formula - $CO-R^{12}$, wherein R^{12} represents hydrogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino or di- C_{1-6} alkylamino;

R⁸ represents hydrogen or C₁₋₆ alkyl;

 R^9 represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-10} aryl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{6-10} aryl- C_{1-6} alkyl, C_{1-6} alkoxy, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, 5- to 10-membered heteroaryl- C_{1-6} alkyl, 3- to 10-membered non-aromatic heterocyclic-

 C_{1-6} alkyl or a group represented by the formula -NR^{11a}R^{11b}, and R⁹ may be substituted with a substituent selected from Substituent Group A or Substituent Group B, wherein R^{11a} and R^{11b} represent the same meaning as recited above;

 V^1 and V^2 may be the same or different and each represents oxygen or sulfur;

10

15

20

25

30

W represents a group represented by the formula $-N(R^{W3})$ -, wherein R^{W3} represents hydrogen or C_{1-6} alkyl;

X represents a group represented by the formula $-C(R^{10})=$ or nitrogen, wherein R^{10} represents hydrogen, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or a group represented by the formula $-CO-R^{12}$, wherein R^{12} represents the same meaning as recited above; and

Y represents oxygen, sulfur, sulfinyl, sulfonyl or a group represented by the formula $-N(R^Y)$ -, wherein R^Y represents hydrogen or C_{1-6} alkyl,

wherein Substituent Group A consists of halogen, hydroxyl, mercapto, nitro, cyano and oxo;

wherein Substituent Group B consists of C_{1-6} alkyl, C_{2-6} alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C₁₋ 6 alkoxy, C₃₋₆ alkenyloxy, C₃₋₆ alkynyloxy, C₃₋₁₀ cycloalkoxy, C₆₋₁₀ aryloxy, 5- to 10-membered heteroaryloxy, 4- to 10-membered nonaromatic heterocyclicoxy, C₁₋₆ alkylthio, C₃₋₆ alkenylthio, C₃₋₆ alkynylthio, C_{3-10} cycloalkylthio, C_{6-10} arylthio, 5- to 10-membered heteroarylthio, 4- to 10-membered non-aromatic heterocyclicthio and a group represented by the formula $-T^1-T^2-T^3$, and each group in Substituent Group B may be substituted with a substituent selected from Substituent Group C, wherein T¹ represents a direct bond or C₁. 6 alkylene, T² represents carbonyl, sulfinyl, sulfonyl, a group represented by the formula -C(=O)-O-, a group represented by the formula -O-C(=O)-, a group represented by the formula -SO₂-O-, a group represented by the formula -O-SO₂-, a group represented by the formula $-NR^{T1}$ -, a group represented by the formula -C(=O)-

 NR^{T1} -, a group represented by the formula $-NR^{T1}$ -C(=O)-, a group represented by the formula $-SO_2$ - NR^{T1} - or a group represented by the formula $-NR^{T1}$ - SO_2 -, T^3 represents hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-10} cycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R^{T1} represents hydrogen or C_{1-6} alkyl, and

wherein Substituent Group C consists of halogen, hydroxyl, mercapto, nitro, cyano, oxo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C_{1-6} alkoxy and C_{1-6} alkylthio.

- 2. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R^1 represents C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.
- 3. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R^1 represents C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group D,

wherein Substituent Group D consists of amino, mono- C_{1-6} alkylamino and di- C_{1-6} alkylamino.

- 4. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R¹ represents a 3- to 10-membered non-aromatic heterocyclic group optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.
- 5. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R^1 represent a group represented by the formula (II):

$$N^{3}$$
 (II)

5

10

15

20

25

wherein a represents an integer of 1 to 4, or a group represented by the formula (III):

5

10

15

20

25

30

wherein b represents an integer of 1 to 3, and Z represents oxygen, sulfur, carbonyl, sulfonyl or a group represented by the formula - NR^{Z} -, wherein R^{Z} represents hydrogen or C_{1-6} alkyl,

and the groups represented by the formula (II) or (III) may be substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.

hydrate of the foregoing, wherein R¹ represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group E, pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group E, piperidin-1-yl optionally substituted with a substituent Group E, azepan-1-yl optionally substituted with a substituent selected from Substituent Group E, azepan-1-yl optionally substituted with a substituent selected from Substituent Group E, piperazin-1-yl optionally substituted with a substituent selected from Substituent Group E, diazepan-1-yl optionally substituted with a substituent Group E, morpholin-4-yl optionally substituted with a substituent selected from Substituent Group E or 1,1-dioxothiomorpholin-4-yl optionally substituted with a substituent selected from Substituent Group E or 1,1-dioxothiomorpholin-4-yl optionally substituted with a substituent selected from Substituent Group E or 1,1-dioxothiomorpholin-4-yl optionally substituted with a substituent selected from Substituent Group E,

wherein Substituent Group E consists of halogen, hydroxyl, mercapto, cyano, formyl, oxo, C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino, di- C_{1-6} alkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl and a group represented by $-T^4-T^5$, wherein T^4 represents carbonyl or sulfonyl, and T^5 represents C_{1-6} alkyl, C_{3-10} cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, hydroxyl, C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino or di- C_{1-6} alkylamino,

where each group included in Substituent Group E may be

substituted with hydroxyl, C_{1-6} alkyl, di- C_{1-6} alkylamino, azetidinyl or pyrrolidinyl.

7. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R¹ represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group E', pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group E', piperidin-1-yl optionally substituted with a substituent selected from Substituent Group E', piperazin-1-yl optionally substituted with a substituent selected from Substituent Group E', diazepan-1-yl optionally substituted with a substituent selected from Substituent Group E' or morpholin-4-yl optionally substituted with a substituent selected from Substituent Group E',

wherein Substituent Group E' consists of methyl, ethyl, dimethylamino, azetidinyl, pyrrolidinyl, piperidinyl and piperazinyl,

where each group included in Substituent Group E' may be substituted with hydroxyl, methyl, dimethylamino, azetidinyl or pyrrolidinyl.

- 8. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R¹ represents a group represented by the formula -NR^{11a}R^{11b}, wherein R^{11a} and R^{11b} represent the same meaning as recited in Claim 1.
- 9. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R^1 represents a group represented by the formula $-NR^{11c}R^{11d}$, wherein R^{11c} represents hydrogen or C_{1-6} alkyl, and R^{11d} represents C_{1-6} alkyl or a group represented by the formula (IV):

5

10

15

25

30

wherein c represents an integer of 1 to 3, and Z^1 represents oxygen, sulfur, carbonyl, sulfonyl or a group represented by the formula - NR^{Z1} -, wherein R^{Z1} represents hydrogen or C_{1-6} alkyl, and R^{11d} may

be substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.

10. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R^1 represents a group represented by the formula $-NR^{11e}R^{11f}$, wherein R^{11e} represents hydrogen or C_{1-6} alkyl, and R^{11f} represents C_{1-6} alkyl, pyrrolidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R^{11f} may be substituted with a substituent selected from Substituent Group E recited in Claim 6.

5

10

15

20

25

30

11. A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R¹ represents a group represented by the formula -NR^{11g}R^{11h}, wherein R^{11g} represents hydrogen or methyl, and R^{11h} represents n-propyl, n-butyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R^{11h} may be substituted with a substituent selected from Substituent Group E",

wherein Substituent Group E" consists of methyl, ethyl, n-propyl, acetyl, dimethylamino, diethylamino, azetidinyl, pyrrolidinyl and piperazinyl,

where each group included in Substituent Group E" may be substituted with methyl or dimethylamino.

- 12. A compound according to any one of Claims 1 to 11, a salt thereof or a hydrate of the foregoing, wherein R^4 , R^5 , R^6 and R^7 may be the same or different and each represents hydrogen, halogen or C_1 . 6 alkyl.
- 13 A compound according to any one of Claims 1 to 12, a salt thereof or a hydrate of the foregoing, wherein R⁸ represents hydrogen.
- 14. A compound according to any one of Claims 1 to 13, a salt thereof or a hydrate of the foregoing, wherein V^1 represents oxygen.
- 15. A compound according to any one of Claims 1 to 14, a salt thereof or a hydrate of the foregoing, wherein X represents a group represented by the formula $-C(R^{10a})=$, wherein R^{10a} represents hydrogen, halogen or cyano.
 - 16. A compound according to any one of Claims 1 to 14, a salt

thereof or a hydrate of the foregoing, wherein X represents nitrogen.

- 17 A compound according to any one of Claims 1 to 16, a salt thereof or a hydrate of the foregoing, wherein Y represents oxygen.
- 18. A compound according to any one of Claims 1 to 17, a salt thereof or a hydrate of the foregoing, wherein V^2 represents sulfur.

5

10

15

25

30

- 19. A compound according to any one of Claims 1 to 17, a salt thereof or a hydrate of the foregoing, wherein W represents a group represented by the formula -NH- and V^2 represents sulfur.
- 20. A compound according to any one of Claims 1 to 17, a salt thereof or a hydrate of the foregoing, wherein V^2 represents oxygen.
- 21. A compound according to any one of Claims 1 to 17, a salt thereof or a hydrate of the foregoing, wherein W represents a group represented by the formula -NH- and V^2 represents oxygen.
- 22. A compound according to any one of Claims 1 to 21, a salt thereof or a hydrate of the foregoing, wherein R^9 represents C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1, C₃₋₁₀ cycloalkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1, C₃₋₁₀ cycloalkyl-C₁₋₆ alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1, C_{6-10} aryl- C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1, 5- to 10-membered heteroaryl-C₁₋₆ alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1or 3- to 10alkyl membered non-aromatic heterocyclic-C₁₋₆ optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.
- 23. A compound according to any one of Claims 1 to 21, a salt thereof or a hydrate of the foregoing, wherein R^9 represents C_{3-10} cycloalkyl- C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in

Claim 1 or C_{6-10} aryl- C_{1-6} alkyl optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in Claim 1.

24. A pharmaceutical composition comprising a compound according to claim 1, a salt thereof or a hydrate of the foregoing.

5

10

15

- 25. An inhibitor for hepatocyte growth factor receptor, comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing.
- 26 An angiogenesis inhibitor comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing.
- 27. An anti-tumor agent comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing.
- 28. An anti-tumor agent according to Claim 27, wherein tumor is a pancreatic cancer, a gastric cancer, a colorectal cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor or an ovarian cancer.
- 29 An inhibitor for cancer metastasis, comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing.